PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025

2025-07医疗健康7免费

📄 文件全名: 《PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025-7页.pdf》
🎯 适合读者: 战略规划行业研究员
📊 核心数据: all medtech subsectors posting median double-digit share price gains or higher—compared with a 9.7% gain for the S&P 500.
Leading the pack were Tempus AI and Exact Sciences, with share price increases of 58% and 57%, respectively, as investors
flocked to higher-risk, higher-reward diagnostic companies. Tempus shares have now climbed nearly 50% since the firm’s IPO
in June 2024. Another company benefiting from renewed investor interest in liquid biopsy is Grail, with gains of 150% since its
🏷️ 核心议题: #医疗

📦 本报告属于月份合集

购买后将获得「2025 年 7 月报告合集」 · 共 2181 份报告打包下载链接

点击获取云盘下载链接

报告摘要

EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research

📋 核心要点(部分)

1 week
30 days
90 days

❓ 常见问题

《PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025》主要包含哪些内容?

EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research核心数据:all medtech subsectors posting median double-digit share price gains or higher—compared with a 9.7% gain for the S&P 500.;Leading the pack were Tempus AI and Exact Sciences, with share price increases of 58% and 57%, respectively, as investors;flocked to higher-risk, higher-reward diagnostic companies. Tempus shares have now climbed nearly 50% since the firm’s IPO。

这份报告覆盖哪一年、篇幅多大?

覆盖 2025 年,全文约 7。

这份报告是免费的吗?如何获取?

本报告免费查阅,登录资料宝后即可在线获取完整内容。

这份报告适合哪些读者?

适合战略规划、行业研究员等读者参考。

报告涉及哪些关键议题?

重点分析了医疗等议题。